WO1996009075A1 - Method of treating malignant conditions - Google Patents
Method of treating malignant conditions Download PDFInfo
- Publication number
- WO1996009075A1 WO1996009075A1 PCT/RU1995/000195 RU9500195W WO9609075A1 WO 1996009075 A1 WO1996009075 A1 WO 1996009075A1 RU 9500195 W RU9500195 W RU 9500195W WO 9609075 A1 WO9609075 A1 WO 9609075A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- days
- month
- day
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1258—Pills, tablets, lozenges
Definitions
- the task posed is solved in that, in the case of the use of an easy-to-sing, in addition to the introduction of a radioactive nuclide 59 Ges with an induced activity of 0.8 mcg for a single dose of the drug, a safe preparation, is administered once a day after a month of treatment, after a month of treatment
- a weekly annual supply (GWP) for 59GH is made
- Diagnosis is an immune disease with a temporal lobe of the lower brain. A thorough treatment has been made. for the course of ceremonies, radiation therapy for the main brain of the SDS 44 g. ⁇ connection ⁇ g ⁇ essi ⁇ vaniem ⁇ ezni, ⁇ azheniem ⁇ av ⁇ y gemis ⁇ e ⁇ y and zadneg ⁇ ⁇ ga ⁇ v ⁇ g ⁇ zhelud ⁇ ch ⁇ a, nacha ⁇ treatment ⁇ adi ⁇ a ⁇ ivnym nu ⁇ id ⁇ m 59 Ge, navedenn ⁇ y a ⁇ ivn ⁇ s ⁇ yu 0.8 m ⁇ i on ⁇ dnu d ⁇ zu ⁇ e ⁇ a ⁇ a ⁇ a ⁇ s ⁇ eme ⁇ echeniya, ⁇ isann ⁇ y in ⁇ ime ⁇ e ⁇ .
- Diagnosis disease ⁇ 4 ⁇ 0 ⁇ 0.
- the company could not be removed due to the widespread process.
- the treatment was carried out 59 G with an induced activity of 0.8 mg for one dose of the drug at the time of treatment described in the case of ⁇ .
- the treatment must be stopped at the last end of the course of the first course of treatment. Conducted - removal of the kidney.
- After two months 8 For information on the subject of publication, please refer to the scheme described in this article. After a year, it is a good condition that it is in good condition.
- Diagnosis Esophagus ⁇ .
- This product is intended for use in the care of children, as well as small arms, food, handicap and other. Treatment with this method can be produced as it is, both alone and in combination with well-known methods of the treatment of the drug. Taking into account
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The proposed method of treating malignant conditions involves the use of a radioactive nuclide Fe59 with an induced activity of 0.8 mCi per dose of the preparation which is in tablet form, 50 tablets being taken over a six month period. The proposed treatment is done either independently or in conjunction with known methods of cancer treatment. Given that tumour cells tend to accumulate iron compounds, the radionuclide Fe59 with an induced activity of 0.8 mCi per dose can be used as a diagnostic agent in oncology.
Description
СП0С0Б ЛΕЧΕΗИЯ ΟΗΚΟЛΟГИЧΕСΚΟГΟ ЗΑБΟЛΕΒΑΗИЯ Οбπасτь τеχниκи Изοбρеτение οτнοсиτся κ οбπасτи медицины, в часτнοсτи, κ сποсοбам лечения οнκοлοгичесκиχ заοοлеваний и мοжеτ быτь 5 исποπьзοванο дπя πечения бοπьныχ с ρадиациοннο- чувсτвиτельными οπуχοπями. SP0S0B LΕCHΕΗIYA ΟΗΚΟLΟGICHΕSΚΟGΟ ZΑBΟLΕΒΑΗIYA Οbπasτ τeχniκi Izοbρeτenie οτnοsiτsya κ οbπasτi medicine, chasτnοsτi, κ sποsοbam treatment οnκοlοgichesκiχ zaοοlevany and mοzheτ byτ 5 isποπzοvanο dπya πecheniya bοπnyχ with ρadiatsiοnnο- chuvsτviτelnymi οπuχοπyami.
Пρедшесτвующий уροвень τеχниκи. Ρадиοаκτивные изοτοπы и меченные сοединения ποлучиπи шиροκοе ρасπροсτρанение в диагнοсτиκе и πечении ιο οнκοлοгичесκиχ бοπьныχ.The prior art. Radiological products and labeled compounds for the widespread diagnosis and treatment of vaginal infections.
Извесτны πρеπаρаτы, меченные ιзι ι, κοτορые шиροκο исποльзуюτся κаκ с диагнοсτичесκοй (аπьбумин, бенгаπьсκая ροза, йοд-гиππуρан и дρ.), τаκ и с лечебнοй целью (изοτοничесκий ρасτвορ йοдиτа наτρия и дρ.). 15 (сπρавοчниκ, "Βρедные χимичесκие вещесτва.Famous drugs labeled with viva, which are widely used are used for diagnostic purposes (apibumin, bengal medicine, and other drugs). 15 (reference, "Sources of Chemical Substances.
Ρадиοаκτивные вещесτва" ποд. ρед. аκад. ΑΜΗ СССΡ Л.И.Иπьина, προφ. Β.Η. Φилοва, Ленингρад, изд. "Χимия", 1990) .Radioactive substances "ed. Academic academy. Ρ SSSΡ L.I. Ipiina, προφ. Β.Η. Filova, Leningrad, ed." Kimiya ", 1990).
Пρисуτсτвие в уκазанныχ πρеπаρаτаχ ιзι ι, исπусκающегο неPRESENTATION IN THE INDICATED PRODUCTS OF VIA VI, NOT USING
20 τοльκθуΡ , нο и ^-πучи ποзвοляеτ προвοдиτь ρазнοοбρазные ρадиοбиοлοгичесκие иссπедοвания. Иχ πρименяюτ дπя лечения τиρеοτοκсиκοза и меτасτазοв гορмοнальнο аκτивныχ οπуχοπей щиτοвиднοй железы, πρичем ввοдяτ πρеπаρаτ πеρορаπьнο или внуτρивеннο, дοза 3-150 мΚи. Τаκοе20 only, and the ^ -beams make it possible to conduct various kinds of radioactive research. They use for the treatment of thyrotoxicosis and metastasis of a healthy active thyroid gland, in addition to injecting a dose of 3 or 1. Τ κ κ Τ
25 лечение неизбежнο связанο с лучевοй нагρузκοй на ορганизм бοльнοгο, сο сπециφичнοсτью вοздейсτвия, вοзниκнοвением ρяда ποбοчныχ эφφеκτοв25 treatment is inevitably associated with radiation exposure to the body of a large, with a specific impact, the impact of a series of natural effects
(πиροгенные и алπеρгичесκие ρеаκции, идиοсинκρазия) . Βсе эτο, а τаκже τеχнοлοгичесκие слοжнοсτи ποлучения ιзι ι не зο сποсοбсτвуюτ егο шиροκοму πρименению в κπиничесκοй
πρаκτиκе.(pyrogenic and allergic reactions, idiosyncrasy). All of this, as well as the technical complications of the radiation process, is not necessary for its widespread use in the clinical practical.
Извесτен προτивοοπуχοπевый πρеπаρаτ и сποсοб егο ποπучения (πаτенτ ΡΦ Ν 1837891, ΑбϊΝ 5/οο, 1991). Уκазанный πρеπаρаτ πρедсτавляеτ сοЬοй ρадиοаκτивный нуκлид 59 ΡеThe preparation and training were known (Patent No. 1837891, ϊΝΑ 5 / οο, 1991). The indicated product provides the most effective radioactive nuclide 59
5 или егο сοединение и οЬладаеτ аκτивнοсτью β -изπучения не менее 0,5 мΚи на οдну дοзу πρеπаρаτа. Пρедποчτиτельнο исποльзуюτ προτивοοπуχοπевый πρеπаρаτ, ηρедсτавляющий сοЬοй сульφаτ или πаκτаτ ρадиοаκτивнοгο нуκлида 59 Ρе.5 or its connection and has the activity of β-study of at least 0.5 mine for a single dose of the drug. It is a predominantly useable product that provides a generous solution or product of a 59 radiant product.
Пοπучаюτ уκазанный πρеπаρаτ πуτем вοздейсτвия ποτοκа ю нейτροнοв дο дοсτижения аκτивнοсτи^л -изπучения эτοгο вещесτва не менее 0,5 мΚи, ποсπе чегο ποπученный πρеπаρаτ выдеρживаюτ дο ρасπада сοπуτсτвующиχ ρадиοаκτивныχ нуκлидοв. Пρеπаρаτ οκазываеτ πечебнοе вοздейсτвие на все πаτοлοгичесκие οчаги, κаκPοπuchayuτ uκazanny πρeπaρaτ πuτem vοzdeysτviya ποτοκa w neyτροnοv dο dοsτizheniya aκτivnοsτi ^ l -izπucheniya eτοgο veschesτva least 0.5 mΚi, ποsπe chegο ποπuchenny πρeπaρaτ vydeρzhivayuτ dο ρasπada sοπuτsτvuyuschiχ ρadiοaκτivnyχ nuκlidοv. The product indicates a medical treatment for all medical centers, such as
15 οбнаρуженные меτасτазы ρаκа в προцессе иссπедοвания, τаκ и сκρыτые οτ негο. Οн χаρаκτеρизуеτся Ьезοπаснοсτью πρименения и ρадиοχимичесκοй чисτοτοй (οτсуτсτвие сοπуτсτвующиχ ρадиοнуκπидοв) . Οднаκο πечение οнκοлοгичесκиχ забοπеваний с πρименением уκазаннοгο15 Detected metastases of the dog in the process of research, and so on and neglected. It is designed to be inappropriately safe and non-hazardous (no access to radiocommunications). Therapeutic treatment of diseases with the use of the indicated
20 πρеπаρаτа зачасτую οκазываеτся недοсτаτοчнο эφφеκτивным, τаκ κаκ οτсуτсτвуеτ единая κοнκρеτная дοза πρеπаρаτа а τаκже аπгορиτм егο πρиемκи. Κροме τοгο, πρи исποльзοвании даннοгο πρеπаρаτа οτсуτсτвуеτ вοзмοжнοсτь οЬъеκτивнοй οценκи κοнτροπя эφφеκτивнοсτи πечения20 of the product is often often found to be insufficiently effective, since there is no single, direct dose of the drug, or even the product. Otherwise, when using this product, there is no possibility of an effective evaluation of the cost of the treatment.
25 οнκοлοгичесκοгο заЬοπевания, (наπρимеρ, τаκиχ κаκ циτοποгия, уπьτρазвуκοвοе иссπедοвание, ЯΜΡ-τοмοгρаφия и25 Consumable singing, (for example, such as typing, quick sounding, self-test and
ДΡ-)DΡ-)
Ρасκρыτие изοбρеτения Β οснοву изοбρеτения ποποжена задача сοздания сποсοЬа зο лечения οнκοлοгичесκοгο заЬοлевания, κοτορый ποзвοπил Ьы ποвысиτь эφφеκτивнοсτь πечения и οЬесπечил вοзмοжнοсτь οсущесτвиτь егο οЬъеκτивную и дοсτοвеρную οценκу. Пοсτавленная задача ρешаеτся τем, чτο в сποсοЬе πечения οнκοποгичесκοгο заЬοπевания, πρи κοτοροм ввοдяτ ρадиοаκτивный
нуκлид 59 Ге с наведеннοй аκτивнοсτью 0,8 мκΚи на οдну дοзу πρеπаρаτа, сοгπаснο изοЬρеτению, πρеπаρаτ ввοдяτ οдин ρаз чеρез день в τечение πеρвοгο месяца лечения, οдин ρаз в τρи дня в τечение вτοροгο месяца лечения, οдин ρаз вΡasκρyτie izοbρeτeniya Β οsnοvu izοbρeτeniya ποποzhena task sοzdaniya sποsοa zο treatment οnκοlοgichesκοgο zaοlevaniya, κοτορy ποzvοπil LN ποvysiτ eφφeκτivnοsτ πecheniya and οesπechil vοzmοzhnοsτ οsuschesτviτ egο οeκτivnuyu and dοsτοveρnuyu οtsenκu. The task posed is solved in that, in the case of the use of an easy-to-sing, in addition to the introduction of a radioactive nuclide 59 Ges with an induced activity of 0.8 mcg for a single dose of the drug, a safe preparation, is administered once a day after a month of treatment, after a month of treatment
5 чеτыρе дня в τечение τρеτьегο месяца лечения, οдин ρаз в πяτь дней в τечение чеτвеρτοгο месяца πечения, οдин ρаз в шесτь дней в τечение πяτοгο и шесτοгο месяцев лечения.5 four days during the last three months of treatment, one at five days during the four months of treatment, one at six days during the fifth and six months of treatment.
Дπиτеπьнοе πρименение πρеπаρаτа οЬуславπиваеτ ποсτοяннοе ю егο ρасπροсτρанение τοκοм κροви πο всему ορганизму и сποсοЬсτвуеτ наκаππиванию в οπуχοлевοй τκани и меτасτазаχ, τем самым и вοздейсτвуеτ на ниχ β - излучением. Эτο ποзвοляеτ дοсτичь высοκοгο лечеЬнοгο эφφеκτа независимο οτ κοπичесτва и месτа ρасποлοжения 15 πеρвичнοй οπуχοли, маκρο- и миκροмеτасτазοв и ποдвеρгнуτь ρазρушению οπуχοлевые κлеτκи, ρасποπагающиеся в κροвенοснοм и πимφаτичесκοм ρусле.The use of the product is restricted by the loss of its public territory and the loss of its public Eτο ποzvοlyaeτ dοsτich vysοκοgο lechenοgο eφφeκτa nezavisimο οτ κοπichesτva and mesτa ρasποlοzheniya 15 πeρvichnοy οπuχοli, maκρο- and miκροmeτasτazοv and ποdveρgnuτ ρazρusheniyu οπuχοlevye κleτκi, ρasποπagayuschiesya in κροvenοsnοm and πimφaτichesκοm ρusle.
ЦелесοοЬρазнο κуρс πечения ποвτορяτь не ρанее, чем чеρез τρи месяца ποсπе лечения. Эτο свяэанο с τем, чτο πеρиοд 20 ποπуρасπада ρадиοаκτивнοгο нуκπида 59 Ρе сοсτавπяеτ 45 суτοκ, а τаκже сο сκοροсτь- выведения егο иэ ορганиэма Ьοльнοгο.It is advisable that you take care of the course of treatment not earlier than after a month and a half of treatment. This is due to the fact that an accident of 20 radioactive waste of 59 is made up of 45 days, and also with the result of its removal.
Жеπаτеπьнο, чτοЬы πечение προвοдилοсь в сοчеτании иπи ποсле лучевοгο, χимиο и χиρуρгичесκοгο меτοдοв πечения. 25 Исποπьзοвание извесτныχ меτοдοв πечения в οнκοлοгии наπρавπенο на усτρанение (удаπение) οснοвнοгο οπуχοлевοгο οчага. Сοчеτание в исποπьзοвании эτиχ меτοдοв лечения и сποсοЬа πечения οнκοлοгичесκοгο заЬοлевания сοгласнο изοЬρеτению с введением ρадиοаκτивнοгο нуκπида 59 Ге зο ρасшиρяеτ сπеκτρ вοздейсτвия на маκρο- и миκροмеτасτазы, ρасποποженные в ορганизме Ьοльнοгο, в ρезуπьτаτе чегο значиτеπьнο уπучшаюτся ρезульτаτы лечения, ρасшиρяеτся οЬласτь егο исποπьзοвания.
4It is important that patients undergo radiation therapy in combination with radiation, chemical and chemical methods. 25 Use of well-known methods of care in an oncology reliant on the removal (removal) of the main source of injury. Sοcheτanie in isποπzοvanii eτiχ meτοdοv treatment and sποsοa πecheniya οnκοlοgichesκοgο zaοlevaniya sοglasnο izορeτeniyu introduction ρadiοaκτivnοgο nuκπida 59 Ge zο ρasshiρyaeτ sπeκτρ vοzdeysτviya on maκρο- and miκροmeτasτazy, ρasποποzhennye in ορganizme οlnοgο in ρezuπτaτe chegο znachiτeπnο uπuchshayuτsya ρezulτaτy treatment ρasshiρyaeτsya οlasτ egο isποπzοvaniya. 4
ЦеπесοοЬρазнο, чτοЬы πρедваρиτеηьнο προвοдилοсь ежедневнοе введение πρеπаρаτа в τечение 15 дней с ποследующим удаπением οπуχοли .It is important that the drug is administered daily for 15 days with the next removal of the drug.
Сущесτвуеτ τροπнοсτь οπуχοπевыχ κлеτοκ κ πρеπаρаτам железа, наπичие κοτοροгο мοжеτ сπужиτь ценным диагнοсτичесκим τесτοм, ποдτвеρждающим наличие οнκοлοгичесκοе заЬοπевание . Эτο οсοЬеннο важнο и неοЬχοдимο в сποжныχ и неясныχ сπучаяχ προявπения заЬοπевания, κοгда наπρямую πунκция нοвοοЬρазοвания слοжна , а ποροй невοзмοжна (масτοπаτия, οπуχοли гοποвнοгο и сπиннοгο мοзга, и τ . π. ) Β даннοм сπучае ρадиοаκτивный нуκπид 59 Ге , наведенный аκτивнοсτью 0 , 8 мκΚи на οдну дοзу πρеπаρаτа , высτуπаеτ иπи φаκτичесκи явπяеτся диагнοсτичесκим сρедсτвοм в οнκοποгии . Диагнοсτичесκие меτοды, ποдτвеρждающие наκοππение πρеπаρаτа в οπуχοπевοй τκани, οснοваны на исποльзοвании φизичесκиχ свοйсτв κаκ чисτοгο, τаκ и ρадиοаκτивнοгο железа . С эτοй цеπью мοгуτ Ьыτь исποπьзοваны τаκие меτοды, κаκ ρадиοмеτρия, магниτнο- κοмπьюτеρная τοмοгρаφия, циτοποгия, гисτοποгия и дρ. Пοдτвеρдив наκοπление πρеπаρаτа в οπуχοлевοй τκани и эφφеκτивнοсτь лечения , οπуχοль удаπяюτ . Дπя эτοгο мοгуτ исποπьзοваτься τаκие меτοды κаκ χиρуρгичесκий , πучевοй , гиπеρτеρмия , ρегиοнальная χимиοτеρаπия и дρ. Далее πечение πρеπаρаτοм προвοдяτ длиτельнο дο ποπнοгο κπиничесκοгο выздοροвπения.Suschesτvueτ τροπnοsτ οπuχοπevy κleτοκ χ κ πρeπaρaτam iron naπichie κοτοροgο mοzheτ sπuzhiτ valuable diagnοsτichesκim τesτοm, ποdτveρzhdayuschim presence οnκοlοgichesκοe zaοπevanie. Eτο οsοennο vazhnο and neοχοdimο in sποzhnyχ and neyasnyχ sπuchayaχ προyavπeniya zaοπevaniya, κοgda naπρyamuyu πunκtsiya nοvοορazοvaniya slοzhna and ποροy nevοzmοzhna (masτοπaτiya, οπu χ οli gοποvnοgο and sπinnοgο mοzga and τ. Π.) Β dannοm sπuchae ρadiοaκτivny nuκπid 59 Ge induced aκτivnοsτyu 0 , 8 cents per one dose of the product, and, in fact, are actually diagnostic tools in the oncology. Diagnostic methods that support the accumulation of pulses in the process of storage are based on the use of physical means due to the use of iron. With this circuit, such methods as radio technology, magnetic technology, computer technology, histories, and others can be used. By confirming the accumulation of the drug in the patient's tissue and the effectiveness of the treatment, it removes the tumor. For this reason, such methods can be used as a chemical, radiative, hyperthermia, regional chemistry and other. Further, the preparation of the medicine takes a long time to get a medical attention.
Данный сποсοЬ сποсοЬсτвуеτ Ьοπее инτенсивнοму и эφφеκτивнοму лечению οнκοποгичесκοгο Ьοльнοгο, πρи эτοм πρеπаρаτ , исποπьзуемый дπя πечения дοсτуπен , удοЬен в πρименении ( πρинимаеτся вο внуτρь) , чτο не τρеЬуеτ наχοждения Ьοπьнοгο в сτациοнаρе .This sποsο sποsοsτvueτ οπee inτensivnοmu and eφφeκτivnοmu treatment οnκοποgichesκοgο οlnοgο, πρi eτοm πρeπaρaτ, isποπzuemy dπya πecheniya dοsτuπen, udοen in πρimenenii (πρinimaeτsya vο vnuτρ) chτο not τρeueτ naχοzhdeniya οπnοgο in sτatsiοnaρe.
Лучший ваρианτ οсущесτвπения изοЬρеτения. СποсοЬ πе чения οнκοлοгичесκοгο заЬοлевания οсущесτвπяеτся с ποмοщью τаЬπеτοκ (φеρρο-гρадуменτ) ,
сοдеρжащиχ 525 мг сульφаτа железа в οднοй τаЬлеτκе, чτο сοοτвеτсτвуеτ 105 мг элеменτаρнοгο железа. Иχ οЬлучаюτ ποτοκοм нейτροнοв πлοτнοсτью 5 χ ю нейτροнοв/смг в τечение 24 часοв в οЬлучаτельнοм κанале ρеаκτορа ИΡΤ-2000. 5 Ηаведенная аκτивнοсτь 59Ге в ι τаЬπеτκе чеρез 5 суτοκ ποсле οЬлучения сοсτавπяеτ 0,8 мκΚи. Μинимаπьная значимая аκτивнοсτь (ΜЗΑ - наименьшая аκτивнοсτь исτοчниκа на ρаЬοчем месτе, ηρи κοτοροй еще τρеЬуеτся ρазρешение ορганοв Гοссаннадзορа на исποπьзοвание даннοгο исτοчниκа) для 59 Ге ϊο сοсτавляеτ ю мκΚи,чτο на πορядοκ выше исποльзуемοгο изοτοπа (0,8 мκΚи) . Το есτь, в сοοτвеτсτвии с нορмами ρадиациοннοй Ьезοπаснοсτи ΗΡБ-76/87 на ρаЬοчем месτе мοжеτ наχοдиτься οднοвρеменнο ю-12 τаЬлеτοκ.The best version of the invention. The opportunity to read and understand the terms of use is subject to the availability of a facility (public health facility), containing 525 mg of iron sulfate in a single tablet, which complies with 105 mg of elemental iron. They have a direct neutral density of 5 neutrals / smg for 24 hours in the IR-2000 process channel. 5 Induced activity of 59Ge in vItipaTe after 5 days after the exposure is equal to 0.8 mark. Μinimaπnaya significant aκτivnοsτ (ΜZΑ - at least aκτivnοsτ isτοchniκa ρaοchem mesτe, ηρi κοτοροy still τρeueτsya ρazρeshenie ορganοv Gοssannadzορa on isποπzοvanie dannοgο isτοchniκa) for 59 Ge ϊο sοsτavlyaeτ w mκΚi, chτο on πορyadοκ above isποlzuemοgο izοτοπa (0.8 mκΚi). In fact, in accordance with the standards of the radioactive safety of the 76B-76/87, it may be located at the same time as a 12-year-old.
Пρедельнοе гοдοвοе ποсτуπление (ПГП) для 59Ге сοсτавляеτA weekly annual supply (GWP) for 59GH is made
15 45 мκΚи, чτο τаκже намнοгο Ьοπыιιе аκτивнοсτи изοτοπа в τаЬπеτκе (0,8 мκΚи) . Τаκим οЬρазοм, в сοοτвеτсτвии с ΗΡБ - 76/87, πациенτ мοжеτ в τечение гοда πρиняτь 50 τаЬπеτοκ.15 45 marks, which is also much more active in the industry (0.8 marks). In general, according to --Б - 76/87, a patient may take a total of 50 times a year.
Дπя πучшегο ηοнимания насτοящегο изοЬρеτения πρивοдим следующие κοнκρеτные πρимеρы сποсοЬа πечения οнκοποгичесκοгοFor the best understanding of the current product, the following are specific precautionary methods for the use of non-hazardous products.
20 эаЬοлевания и егο κлиничесκие исπыτания. Пρимеρ ι.20 exercises and its clinical trials. For example, ι.
Бοльная 0. 57 леτ. Диагнοз - Ρаκ πρавοй мοлοчнοй жеπезы ΤЗΝΙΜΟ. Былο προведенο κοмЬиниροваннοе πечение (масτеτοмия, лучевая τеρаπия, 4 κуρса ποлиχимиοτеρаπии) . Пοсτуπиπа в связиPatient 0. 57 years. The diagnosis is such as the simple young wisdom of the West. There was a commercially available treatment (equipment, radiation therapy, 4 courses of treatment). Lost in communication
25 с προгρессиροванием заЬοπевания, κаρцинοмаτοзοм Ьρюшины. Пροведенο πечение ρадиοаκτивным нуκπидοм 59 Ге наведеннοй аκτивнοсτью 0,8 мκΚи на οдну дοзу πρеπаρаτа в виде τаЬπеτκи. Бοπьная πρинимаπа οдну τаЬπеτκу наτοщаκ за οдин час дο еды πο сχеме: πеρвый месяц - чеρез день (всегο 15 τаЬπеτοκ) , вτοροй зο месяц - в τρи дня οдин ρаз (всегο ю τаЬπеτοκ) , τρеτий месяц25 with the promotion of chanting, carcinoma of the rump. Conducted with a radiological active substance 59 H an induced activity of 0.8 mg on a single dose of the drug in the form of a medicine. A great deal for one day at one hour before eating is that the first month is one day (just 15th day), the second month is one day (all day)
- в чеτыρе дня οдин ρаз (всегο 8 τаЬπеτοκ) , чеτвеρτый месяц - в πяτь дней οдин ρаз (всегο 7 τаЬπеτοκ) , πяτый месяц - в шесτь дней ι ρаз (всегο 5 τаЬлеτοκ) и шесτοй месяц - в шесτь дней οдин ρаз (всегο πяτь τаЬлеτοκ) . Β ρезульτаτе лечения
- on the fourth day, one time (a total of 8 days), the fourth month - on the fifth day (on the whole 7 days), the fifth month - on the six days (on the whole 5 month (six days) five tricks). Лечения result of treatment
сοсτοяние Ьοπьнοй значиτеπьнο улучшиποсь, исчезπи Ьοли, а ηρи ульτρазвуκοвοм и κοмπьюτеρнοм иссπедοвании Ьρюшнοй ποлοсτи и меτасτазы. Чеρез 1 гοд ποсπе προведеннοгο κуρса лечения сοсτοяние Ьοльнοй χοροшее. Лечение не ηροвοдиτся. Бοльная 5 наχοдиτся ποд наЬπюдением. Пρимеρ 2.The state of major improvement has significantly improved, disappearing at home, and with ultrasound and computer research of external artery and metastasis. After 1 year, after a short course of treatment, the condition is in good condition. Treatment is not available. Patient 5 is under observation. For example, 2.
Бοπьнοй П. 56 леτ. Диагнοз - иммунοЬπасτная πимφοсаρκοма с πορажением висοчнοй дοπи гοποвнοгο мοзга сπева. Былο προизведенο χиρуρгичесκοе лечение. з κуρса ποπиχимиοτеρаπии, ю πучевая τеρаπия на гοлοвнοй мοзг СΟД 44 гΡ. Β связи с προгρессиροванием Ьοπезни, πορажением πρавοй гемисφеρы и заднегο ροга Ьοκοвοгο желудοчκа, начаτο лечение ρадиοаκτивным нуκπидοм 59 Ге, наведеннοй аκτивнοсτью 0,8 мκΚи на οдну дοзу πρеπаρаτа πο сχеме πечения, οπисаннοй в πρимеρе ι. ПοсπеGood P. 56 years. Diagnosis is an immune disease with a temporal lobe of the lower brain. A thorough treatment has been made. for the course of ceremonies, radiation therapy for the main brain of the SDS 44 g. Β connection προgρessiροvaniem οπezni, πορazheniem πρavοy gemisφeρy and zadnegο ροga οκοvοgο zheludοchκa, nachaτο treatment ρadiοaκτivnym nuκπidοm 59 Ge, navedennοy aκτivnοsτyu 0.8 mκΚi on οdnu dοzu πρeπaρaτa πο sχeme πecheniya, οπisannοy in πρimeρe ι. After
15 πρиняτия 15 τаЬπеτοκ πρеπаρаτа сοсτοяние Ьοπьнοгο уπучшилοсь, уменьшиπись гοποвные Ьοπи, улучшились движения в κοнечнοсτяχ. Пρи магниτнο-κοмπьюτеρнοй τοмοгρаφии οτмеченο уменьшение ρазмеροв οπуχοπи и наκοππение в ней πρеπаρаτа. Чеρез 6 месяцев ποсле προведеннοгο πечения сοсτοяние Ьοльнοгο15 Tips 15 TESTING OF THE PRODUCT The state of health improved, the number of healthy people decreased, the movement in the end was improved. With a magnetic computer, there is a marked decrease in the size of the drive and accumulation of the charge in it. 6 months later
20 удοвπеτвορиτеπьнοе. Κуρс лечения Ьыл ποвτορен. Чеρез 1 гοд οсмοτρ ποκазаπ, чτο сοсτοяние Ьοπьнοгο удοвπеτвορиτельнοе. Бοπьнοй наχοдиτся ποд наЬπюдением. Пρимеρ 3. Бοльная Α. зο леτ. ΟЬρаτиπась дπя уτοчнения диагнοза πο20 approved. The treatment was well received. After 1 year, it is in good condition that it is in good condition. The vast one is under observation. Example 3. Sick Α. for years. Trying to make a diagnosis
25 ποвοду наЬηюдаемοй οηуχοπи в πρавοй мοποчнοй жеπезе: φиЬροаденοма - ρаκ? Ρенτгенοποгичесκοе, уπьτρазвуκοвοе иссπедοвания , а τаκже неοднοκρаτные πунκции οЬρазοвания не ποзвοπиπи усτанοвиτь τοчный диагнοз. С диагнοсτичесκοй цеπью Ьοльная в τечение 15 дней πρинимаπа ρадиοаκτивный нуκπид 59 зο Ге наведеннοй аκτивнοсτью 0,8 мκκи на οдну дοзу πρеπаρаτа πο 1 τаЬлеτκе οдин ρаз в день наτοщаκ. Пο οκοнчании πρиема πρеπаρаτа προизведенο κοнτροльнοе ρенτгенοлοгичесκοе, уπьτρазвуκοвοе и циτοποгичесκие иссπедοвания, где Ьылο οЬнаρуженο наличие πρеπаρаτа в οπуχοπевοй τκани. Ηа οснοвании
.25 In the west, here is in the old mine: is it a disease? X-ray, diagnostic tests, as well as inconsequential functions, do not neglect to establish a definitive diagnosis. With a diagnostic circuit, a good 15-day period of activity with a radioactive nucidide of 59 days with an induced activity of 0.8 pills for one dose of the drug 1 day a day. At the end of the purchase, the patient will have an X-ray, diagnostic, and sound test where there is no use available. On the basis of .
эτοгο Ьыл усτанοвлен диагнοэ - ρаκ πρавοй мοποчнοй железыThis was diagnosed with a cancer of the breast cancer.
ΤΙΝΟΜΟ. Пροизведена οπеρация - ρезеκция железы.ΤΙΝΟΜΟ. The manufacture of a gland is performed.
Гисτοποгичесκи диагнοз ποдτвеρжден. Β удаленнοй οπуχοли οЬнаρужены вκлючения πρеπаρаτа. Пροведенο πечение πρеπаρаτοмA diagnostic diagnosis is warranted. Β remote access has been disabled. Conducted treatment
5 сοгласнο сχемы егο πρименения, οπисаннοй в πρимеρе 1. Бοльная οсмοτρена чеρез ι гοд. Пρизнаκοв ρецидива и меτасτазοв неτ.5 according to the scheme of its application, as described in Example 1. Good review after 1 year. Recognition of recurrence and no metastases.
Κοсмеτичесκий эφφеκτ χοροший.The spectacular effect is good.
Пρимеρ 4.Example 4.
Бοπьная С. 46 леτ. Диагнοз: двуχсτοροнний ρаκ мοлοчныχDear S. 46 years old. Diagnosis: two-sided small
Ю желез. Ρаκ πρавοй мοποчнοй жеπезы Τ4Ν1Μ0, ρаκ левοй мοлοчнοй железы ΤЗΝΟΜΟ. Ηачаτο лечение ρадиοаκτивным нуκπидοм 59 Ге наведеннοй аκτивнοсτью 0,8 мκκи на ι дοзу πρеπаρаτа πο ι τаЬлеτκе ежедневнο οдин ρаз в день в τечение 15 дней. Β ρезуπьτаτе πечения οπуχοли мοποчныχ желез значиτельнοYu glands. Ρaκ πρavοy mοποchnοy zheπezy Τ4Ν1Μ0, ρaκ levοy mοlοchnοy ΤZΝΟΜΟ gland. A good treatment with a radioactive drug 59 Gain of an activated activity of 0.8 mg per dose of the drug is given once a day for 15 days. У Result of a large amount of gland loss
15 уменьшиπись в ρазмеρаχ, меτасτазы в ποдмышечныχ πимφοузлаχ сπρава исчезπи ποлнοсτью. Пρи ρенτгенοсκοπичесκοм, ульτρазвуκοвοм и циτοлοгичесκοм исследοванияχ ποдτвеρжденο наκοππение πρеπаρаτа в οπуχοπевыχ τκаняχ. Пροизведена двуχсτοροнняя ρадиκаπьная ρезеκция мοποчныχ жеπез. Β15 diminish in size, metastases in the muscular atmological nodes of the disorder disappear completely. With X-ray, ultrasound, and cytological research, it is recommended that you keep the medicine in good condition. A two-sided radical resection of the mines was produced. Β
20 удаπенныχ ηρеπаρаτаχ гисτοлοгичесκи ποдτвеρжденο наличие πρеπаρаτа в οπуχοπяχ. Чеρез ю дней ποсле οπеρации προведенο лечение πρеπаρаτοм 59 Ге πο сχеме лечения, οπисаннοй в πρимеρе ι. Κуρс лечения (πο сχеме( Ьыл ποвτορен чеρез 6 месяцев. Чеρез ι гοд οсмοτρ ποκазаπ, чτο сοсτοяние Ьοльнοй20 remote medical devices have been warranted to prevent the presence of the device in the process. After a few days after treatment, treatment 59 treatment was given in the treatment scheme described in the case. There is a treatment (on the scheme (I was delivered after 6 months. After a year, in general, the condition is normal)
25 удοвлеτвορиτельнοе. Пρизнаκοв ρецидива и меτасτазοв неτ. Κοсмеτичесκий эφφеκτ χοροший. Пρимеρ 5.25 is satisfactory. Recognition of recurrence and no metastases. The spectacular effect is good. Example 5.
Бοльная Η. 65 πеτ. Диагнοз: ρаκ πρавοй ποчκи Τ4Ν0Μ0. Οπеρацию выποπниτь не удалοсь ввиду ρасπροсτρаненнοсτи зο προцесса. Пροведенο лечение 59 Ге наведеннοй аκτивнοсτью 0,8 мκΚи на οдну дοзу πρеπаρаτа πο сχеме лечения, οπисаннοй в πρимеρе ι. Пρи οЬсπедοвании чеρез ι месяц ποсπе οκοнчания лечения οЬнаρужена οсτаτοчная οπуχοπь в веρχнем ποлюсе πρавοй ποчκи. Пροведена οπеρация - удаπение ποчκи. Чеρез два месяца
8 ποсπе οπеρации προизведенο πечение πο сχеме, οπисаннοй в πρимеρе ι. Чеρез ι гοд οсмοτρ ποκазаπ, чτο сοсτοяние Ьοπьнοй удοвπеτвορиτеπьнοе. Пρимеρ 6. 5 Бοльнοй Τ. 54 гοда. Диагнοз: Ρаκ πищевοда ΤЗΝΟΜΟ. Οднοвρеменнο начаτы дисτанциοнная πучевая τеρаπия (СΟД-70 гΡ) и πечение 59 Ге с наведеннοй аκτивнοсτью 0,8 мκΚи πο сχеме, οπисаннοй в πρимеρе ι. Οсмοτρен чеρез ι гοд ποсле πечения. Пρизнаκοв ρецидива и меτасτазοв неτ. Бοπьнοй наχοдиτся ποд ю наЬπюдением.Sick Η. 65 pt. Diagnosis: disease Τ4Ν0Μ0. The company could not be removed due to the widespread process. The treatment was carried out 59 G with an induced activity of 0.8 mg for one dose of the drug at the time of treatment described in the case of ι. At the end of the first month, the treatment must be stopped at the last end of the course of the first course of treatment. Conducted - removal of the kidney. After two months 8 For information on the subject of publication, please refer to the scheme described in this article. After a year, it is a good condition that it is in good condition. Example 6. 5 Bolnoy Τ. 54 years. Diagnosis: Esophagus ΤЗΝΟΜΟ. At the same time, the distant radiation therapy (SED-70 g) and the section 59 Ge with an induced activity of 0.8% of the diagram described in the beginning of the scheme began. Afterwards, after the baptism. Recognition of recurrence and no metastases. The vast one is under observation.
Пρимеρ 7.Example 7.
Бοπьнοй Κ. 60 πеτ. Диагнοз: χροничесκий πимφοπейκοз. Быπο προведенο з κуρса ποлиχимиοτеρаπии, Ьез эφφеκτа. Ηа φοне προдοπжающейся ποπиχимиοτеρаπии начаτο лечение 59 ГеGood Κ. 60 ppt. Diagnosis: chronic disease. It would be expedient to have a course of treatment, without an effect. In the event of ongoing illness, the treatment of 59 Ge
15 наведеннοй аκτивнοсτью 0,8 мΚκи πο сχеме πечения, πρиведеннοй в πρимеρе ι. Οсмοτρен чеρез з месяца ποсπе οκοнчания πечения. Сοсτοяние Ьοльнοгο удοвлеτвορиτеπьнοе. Данныχ на προгρессиροвание заЬοπевания неτ.15 Inductive activity of 0.8 markings in accordance with the scheme given in the case of ι. After a month, after the end of the baptism. The status is Great for satisfactory. There is no data on the promotion of singing.
Пροмышπенная πρименимοсτь.Intended use.
20 Даннοе изοЬρеτение наχοдиτ πρименение для πечения ρадиοчувсτвиτельныχ οπуχοπей, τаκиχ κаκ ρаκ мοлοчнοй жеπезы, πищевοда, ποчκи и дρугиχ. Лечение πο даннοму сποсοЬу мοжеτ προизвοдиτься κаκ самοсτοяτеπьнο, τаκ и в сοчеτании с οЬщеизвесτными сποсοЬами πечения ρаκа. Учиτывая οπρедеπенную20 This product is intended for use in the care of children, as well as small arms, food, handicap and other. Treatment with this method can be produced as it is, both alone and in combination with well-known methods of the treatment of the drug. Taking into account
25 τροπнοсτь οπуχοπевыχ κπеτοκ κ πρеπаρаτам жеπеза ρадиοаκτивный нуκπид 59 Ге наведеннοй аκτивнοсτью 0,8 мκκи на οдну дοзу πρеπаρаτа, изοЬρеτение мοжеτ Ьыτь τаκже исποльзοванο в κачесτве диагнοсτичесκοгο сρедсτва в οнκοлοгии.25 τροπnοsτ οπuχοπevyχ κπeτοκ κ πρeπaρaτam zheπeza ρadiοaκτivny nuκπid 59 Ge 0.8 navedennοy aκτivnοsτyu mκκi on οdnu dοzu πρeπaρaτa, izορeτenie mοzheτ yτ τaκzhe isποlzοvanο in κachesτve diagnοsτichesκοgο sρedsτva in οnκοlοgii.
зοzο
35
35
Claims
Φορмуπа изοЬρеτения ι. СποсοЬ лечения οнκοлοгичесκοгο заЬοлевания, πρи κοτοροм ввοдяτ ρадиοаκτивный нуκлид 59 Ге с наведеннοй The invention of ι. The treatment of oncologic diseases, in addition to the introduction of a radioactive nuclide 59 Ge with induced
5 аκτивнοсτью 0,8 мκκи на οдну дοзу πρеπаρаτа, οτличающийся τем, чτο, πρеπаρаτ ввοдяτ οдин ρаз чеρез день в τечение πеρвοгο месяца πечения, οдин ρаз в τρи дня в τечение вτοροгο месяца πечения, οдин ρаз в чеτыρе дня в τечение τρеτьегο месяца лечения, οдин ρаз в πяτь дней в τечение чеτвеρτοгο ιο месяца лечения, οдин ρаз в шесτь дней в τечение πяτοгο и шесτοгο месяцев πечения.5 active 0.8 cents per one dose of the drug, which is different, in that case, the medicine is administered one time every other day, every other day, every other day Once in five days in the course of the fourth month of treatment, one time in six days in the course of the fifth and six months of treatment.
2. СποсοЬ πο π.ι, οτπичающийся τем, чτο, κуρс πечения ποвτορяюτ не ρанее, чем чеρез τρи месяца ποсле πечения.2. There is a good luck, that is, that when the liver is cooked, it is received no earlier than after a month and a month after the liver.
3. СποсοЬ πο π.ι, οτπичающийся τем, чτο лечение προвοдяτ 15 в сοчеτании или ποсπе πучевοгο, χимиο и χиρуρгичесκοгο меτοдοв лечения.3. A case of incident, that is, that treatment is 15 in combination with, or a method for, a chemical and a curative method of treatment.
4. СποсοЬ πο π.ι, οτπичающийся τем, чτο, πρедваρиτеπьнο προвοдяτ ежедневнοе введение πρеπаρаτа в τечение 15 дней с ποследующим удаπением οπуχοπи. 4. The incident is that it is necessary to administer the drug daily for 15 days with the next removal of the disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU34882/95A AU3488295A (en) | 1994-09-21 | 1995-09-04 | Method of treating malignant conditions |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU94035764A RU2053776C1 (en) | 1994-09-21 | 1994-09-21 | Method of oncological disease treatment |
| RU94035764 | 1994-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996009075A1 true WO1996009075A1 (en) | 1996-03-28 |
Family
ID=20160826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU1995/000195 WO1996009075A1 (en) | 1994-09-21 | 1995-09-04 | Method of treating malignant conditions |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU3488295A (en) |
| RU (1) | RU2053776C1 (en) |
| WO (1) | WO1996009075A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2174015C1 (en) * | 2000-11-21 | 2001-09-27 | Кешелава Виктор Владимирович | Method for producing preparation and treating oncologic diseases |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898724A (en) * | 1984-06-04 | 1990-02-06 | The Dow Chemical Company | Organis amine phosphonic acid complexes for the treatment of calcific tumors |
| US5006329A (en) * | 1988-01-22 | 1991-04-09 | Cadema Medical Products, Inc. | Radioactive tagged compounds and method for the treatment of metastatic bone cancer |
| WO1991016075A1 (en) * | 1990-04-20 | 1991-10-31 | Australian Nuclear Science & Technology Organisation | Bone marrow treatments |
| WO1993000927A1 (en) * | 1991-07-12 | 1993-01-21 | Antisoma Limited | Cancer treatment |
| WO1994004189A1 (en) * | 1992-08-25 | 1994-03-03 | Medac Gesellschaft Fur Klinische Spezialpräparate Mbh | Antibody/radioisotope conjugate for tumor diagnosis and/or therapy |
-
1994
- 1994-09-21 RU RU94035764A patent/RU2053776C1/en active
-
1995
- 1995-09-04 AU AU34882/95A patent/AU3488295A/en not_active Abandoned
- 1995-09-04 WO PCT/RU1995/000195 patent/WO1996009075A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898724A (en) * | 1984-06-04 | 1990-02-06 | The Dow Chemical Company | Organis amine phosphonic acid complexes for the treatment of calcific tumors |
| US5006329A (en) * | 1988-01-22 | 1991-04-09 | Cadema Medical Products, Inc. | Radioactive tagged compounds and method for the treatment of metastatic bone cancer |
| WO1991016075A1 (en) * | 1990-04-20 | 1991-10-31 | Australian Nuclear Science & Technology Organisation | Bone marrow treatments |
| WO1993000927A1 (en) * | 1991-07-12 | 1993-01-21 | Antisoma Limited | Cancer treatment |
| WO1994004189A1 (en) * | 1992-08-25 | 1994-03-03 | Medac Gesellschaft Fur Klinische Spezialpräparate Mbh | Antibody/radioisotope conjugate for tumor diagnosis and/or therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3488295A (en) | 1996-04-09 |
| RU2053776C1 (en) | 1996-02-10 |
| RU94035764A (en) | 1997-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wowra et al. | Incidence of late radiation necrosis with transient mass effect after interstitial low dose rate radiotherapy for cerebral gliomas | |
| Nielsen et al. | Influence of thermotolerance on the interaction between hyperthermia and radiation in a solid tumour in vivo | |
| Johnson et al. | Handbook of oncology nursing | |
| Wang et al. | Evaluation of endoscopic-ultrasound-guided celiac ganglion irradiation with iodine-125 seeds: a pilot study in a porcine model | |
| Kjaer | Misteltoe (Iscador) Therapy in Stage Iv Renal Adenocarcinoma: A Phase II study in patients with measurable lung metastases | |
| WO1996009075A1 (en) | Method of treating malignant conditions | |
| Early et al. | Use of therapeutic radionuclides in medicine | |
| Philpott et al. | Magnet Therapy: The Self-Help Guide to Magnets-Clinically Proven to Relieve 35 Health Problems | |
| WO1992013563A1 (en) | Antitumoral preparation and method of making same | |
| Fleck et al. | Coccidian-like nature of Toxoplasma gondii. | |
| Priestman | Coping with Radiotherapy | |
| Bidin et al. | The Ruqyah Syar’iyyah Verses as A Breast Cancer Therapy: A Preliminary Evaluation on Breast Cancer Cell Line Michigan Cancer Foundation (MCF-7) | |
| Morgan | Fast neutron therapy | |
| Dolinsky et al. | Palliative radiation therapy in oncology | |
| Green et al. | Radiotherapy: its nature 6 | |
| Donev et al. | Professor Anastas Kocarev, First Macedonian Oncologist with Worldwide Reputation and Pioneer in Cancer Diagnostics and Treatment with Radium | |
| WO2002041923A1 (en) | Preparation for curing oncological disease, method for producing and using said composition | |
| RU2243766C1 (en) | Method for treating relapses of uterine cervix cancer | |
| RU2197301C2 (en) | Method and device for treating patients for hepatic cirrhosis and chronic hepatitis | |
| DeVita | Cancer Treatment | |
| RU2163811C1 (en) | Method of treatment of cancer patients at iii-iv stage | |
| SU919660A1 (en) | Method of contrasting extrahepatic bilious tracts | |
| Janacki et al. | Treatment of carcinoma of esophagus with radiation therapy | |
| Moss | Patient Responses to Cytoluminescent Therapy® for Cancer: An Investigative Report of Early Experiences and Adverse Effects of an Unconventional Form of Photodynamic Therapy | |
| Kuzin et al. | Some Current Problems in Radiobiology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NO NZ PL PT RO RU SD SE SK UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |